AMGEN-AMG-509-20230005
Phase III
OPEN TO ACCRUAL
A Phase 3, Open-Label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Chemotherapy
BMS-CA071-1000-RECHARGE
Phase III
OPEN TO ACCRUAL
A Phase 3, Two-Part, Randomized, Open-Label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - rechARge
JANUX-PSMA-007-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
MERCK-MK-2400-001
Phase III
OPEN TO ACCRUAL
A Phase 3, Open-Label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
NOVARTIS-CAAA817A12201-PSMACT
Phase II/III
OPEN TO ACCRUAL
A Phase II/III, Open-Label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NOVARTIS-CAAA817B12301-ACTFIRS
Phase III
OPEN TO ACCRUAL
AcTFirst: A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Ccastration Resistant Prostate Cancer
REGENERON-R4336-ONC-20104
Phase I/II
OPEN TO ACCRUAL
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer